APOLLOMICS INC. CLASS A ORDINARY SHARES
NASDAQ: APLM (Apollomics Inc.)
最近更新时间: 2小时之前20.69
-0.11 (-0.53%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Apollomics Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.5 |
| 技术平均移动指标 | -5.0 |
| 技术振荡指标 | -0.5 |
| 相对估值 | NA |
| 财务健康 | -1.4 |
| 宏观环境 | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -1.81 |
|
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 36.50% |
| 机构持股比例 | 0.22% |
该时间范围内无数据。
投资组合